Arlene O. Siefker-Radtke, MD

Arlene O. Siefker-Radtke, MD, discusses the latest breakthroughs in bladder cancer treatment with erdafitinib, an FGFR1-4 inhibitor.

Arlene O. Siefker-Radtke, MD, dives into the background and the cohorts included in the phase 3 THOR study.

Arlene O. Siefker-Radtke, MD, discusses the results of the phase 3 THOR study of erdafitinib vs pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations.

Arlene Siefker-Radtke, MD, highlights the ongoing quest for improved treatment options in metastatic urothelial cancer, emphasizing the role of clinical trials and novel agents in addressing unmet needs.

Expert perspective on the impact of neuropathy on treatment choices in urothelial cancer, providing insight into identifying and managing peripheral neuropathy and exploring suitable treatment options.

Arlene Siefker-Radtke, MD, delves into the complexities of managing progressive disease in metastatic urothelial cancer, outlining considerations for immune checkpoint inhibitors, antibody drug conjugates, and other targeted therapies.

Diverse approaches to frontline treatment for metastatic urothelial cancer, including eligibility for cisplatin-based chemotherapy, alternative regimens, and the impact of drug shortages on treatment decisions.

Arlene Siefker-Radtke, MD, emphasizes the importance of early mutation profiling in metastatic urothelial cancer and highlights the potential for targeted agents and clinical trials to improve treatment outcomes.

The evolving role of biomarker testing, including PD-L1 expression and mutations like FGFR3, in guiding treatment decisions for urothelial cancer patients, shedding light on their clinical significance and potential impact on therapeutic choices.

Expert insight into the complexities of managing metastatic urothelial cancer in geriatric patients with comorbidities, highlighting the importance of aggressive therapy in improving survival outcomes.

Arlene Siefker-Radtke, MD, discusses the nuanced treatment journey of a 73-year-old man with metastatic bladder cancer, highlighting the challenges and evolving strategies in his case.

Arlene O. Siefker-Radtke, MD, discusses the data seen with sacituzumab govitecan, an antibody-drug conjugate that targets TROP-2, which is expressed frequently in urothelial cancer cells.

Arlene O. Siefker-Radtke, MD, professor of genitourinary medical oncology at MD Anderson Cancer Center, discusses the results presented at the 2018 ASCO Annual Meeting from a phase II cohort investigating erdafitinib in previously treated patients with urothelial cancer. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that targets FGFR 1 through 4 and has previously shown promising activity. 

Siefker-Radtke says her preferred mathod of neoadjuvant chemotherapy is doxorubicin plus ifosfamide with an alternating regimen of etoposide cisplatin.